Skip to content
OpenCapital
Get started

Tango Therapeutics TNGX Personnel-Related Expenses-RD — Research And Development Expense

Other segment segments

Vopimetostat Direct Program Expenses-RD
$9.33M+70.9%
Facilities And Other Related Expenses-RD
$4.34M-20.6%
TNG456Direct Program Expenses-RD
$2.06M+55.8%
TNG260Direct Program Expenses-RD
$2.01M+16.1%
Discovery Direct Program Expenses-RD
$1.87M-60.0%
TNG908Direct Program Expenses-RD
$581K-66.1%
TNG961Direct Program Expenses-RD
$408K-81.6%

Similar metrics at other companies

Dianthus Therapeutics logo
DNTHPersonnel And Related Costs — Research And Development Expense
$8.64M+47.7%
Scholar Rock logo
SRRKRD Expense Srk439 — Research And Development Expense
$1.76M-58.9%
Scholar Rock logo
SRRKEarly Research — Research And Development Expense
$1.21M-16.8%
Cogent Biosciences, Inc. logo
COGTResearch And Development Personnel Related — Operating Income
$18.05M+21.3%
Dianthus Therapeutics logo
DNTHDiscovery Expenses — Research And Development Expense
$1.36M+51.4%
Repligen logo
RGENR&D
$14.46M+19.3%

Other financials

Income statement

See full
Revenue--100%
Operating income-$48.8M-14.7%
Net income-$45.5M-14.1%
EPS (diluted)-$0.32+11.1%

Balance sheet

See full
Cash & equivalents$160.0M+162%
Total debt$32.8M-11.3%
Total equity$391.5M+135%
Total assets$435.8M+58.9%

Cash flow

See full
Operating cash flow-$44.4M-6.4%
CapEx-$2.0K-104%
Free cash flow-$44.4M-6.3%

Valuation

See full
Market cap$4.55B+1,915%
Enterprise value$4.43B+2,204%
P/S79.9×+74.4×

Profitability

See full
Operating margin-206.2%-61.0pp
Net margin-188.2%-55.4pp
FCF margin-250.1%-49.4pp

Returns & leverage

See full
Return on equity-38.4%-10.5pp
Debt / equity0.1×-0.1×
Current ratio27.4×+21.1×

Where this comes from

Reported directly by Tango Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Tango Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tango Therapeutics's personnel-related expenses-rd — research and development expense.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tango Therapeutics's personnel-related expenses-rd — research and development expense?
Tango Therapeutics (TNGX) reported personnel-related expenses-rd — research and development expense of $12.93M in Q1 2026.
How has Tango Therapeutics's personnel-related expenses-rd — research and development expense changed year-over-year?
Tango Therapeutics's personnel-related expenses-rd — research and development expense decreased by 6.6% year-over-year, from $13.85M to $12.93M.
What is the long-term trend for Tango Therapeutics's personnel-related expenses-rd — research and development expense?
Over 3 years (2022 to 2025), Tango Therapeutics's personnel-related expenses-rd — research and development expense has grown at a 22.2% compound annual growth rate (CAGR), from $28.19M to $51.47M.
What does personnel-related expenses-rd — research and development expense mean?
This metric represents the total compensation and benefits costs allocated specifically to the research and development function within the organization. It captures the investment in human capital required to drive drug discovery, clinical trial execution, and scientific innovation. Monitoring this figure provides insight into the company's commitment to internal talent development and the operational intensity of its pipeline advancement efforts.